The orexins/hypocretins and schizophrenia.
Advances in molecular biology have led to new peptides and proteins being discovered on a regular basis, including the isolation of a number of neurotransmitter candidates. Rarely, however, do these immediately capture the attention of the scientific community. The isolation and characterization of the orexin/hypocretin peptides a decade ago resulted in a slew of studies that have helped clarified their diverse functions, including prominent roles in arousal and appetitive behavior. A number of recent studies have detailed the role of the orexins/hypocretins in attention and cognition and uncovered an involvement in schizophrenia and the mechanisms of action of antipsychotic drugs (APDs). This issue of Schizophrenia Bulletin presents several articles that review our current understanding and point to future directions for the study of the orexins/hypocretins in schizophrenia and APD actions.
Deutch
Ariel Y
AY
Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN 37212, USA. ariel.deutch@vanderbilt.edu
Bubser
Michael
M
D001559:Benzhydryl Compounds / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics* / Q000378:metabolism*; D000077408:Modafinil; D009479:Neuropeptides / Q000235:genetics* / Q000378:metabolism*; D000068797:Orexins; D012559:Schizophrenia / Q000235:genetics* / Q000378:metabolism*
D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D000068797:Orexins; D000077408:Modafinil